Drug Profile
MEB 1166
Alternative Names: MEB-1166Latest Information Update: 02 Feb 2023
Price :
$50
*
At a glance
- Originator MEBIAS Discovery
- Class Analgesics
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 02 Feb 2023 MEB 1166 is still in preclinical study for Pain in US (unspecified) (MEBIAS Discovery pipeline, February 2023)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Pain in USA (SC)
- 19 Oct 2017 MEB 1166 is available for licensing as of 19 Oct 2017. www.mebiasdiscovery.com